#Canada #Calgary #MolecuLight #SnapshotGLO® #Kent Imaging

Kent Imaging Defends SnapshotGLO® Against Patent Claims

Kent Imaging, a prominent player in diagnostic imaging technology, has publicly responded to a patent infringement complaint filed by MolecuLight Corp. and MolecuLight Inc. with the U.S. International Trade Commission (ITC). This complaint revolves around Kent Imaging's SnapshotGLO®, a device that recently achieved FDA 510(k) clearance. MolecuLight alleges that SnapshotGLO® infringes on a patent for which they claim to hold a licensing agreement.

Despite these assertions, Kent Imaging vehemently denies the allegations, expressing confidence that MolecuLight's claims lack substance. Pierre Lemire, CEO of Kent Imaging, reinforced the company's strong commitment to respecting intellectual property rights while emphasizing their determination to defend their position. "Kent's Snapshot product line, including SnapshotGLO, reflects years of disciplined research and patented innovation," stated Lemire. He affirmed that the company remains focused on delivering technologies that significantly improve patient outcomes.

SnapshotGLO® and its partner device, SnapshotNIR®, exemplify Kent's dual-modality approach to diagnostic imaging, which enhances the science of wound care with improved clinical decision-making. SnapshotGLO® specializes in bacterial autofluorescence imaging, delivering crucial real-time insights into wound bioburden. With both technologies working in tandem, clinicians gain a more comprehensive understanding of patient needs, ultimately resulting in better healthcare delivery.

Growth and Commitment to Innovation

Kent Imaging has seen robust growth in recent years, largely driven by its continuous investment in research and development. The company is dedicated to creating innovative tools that assist clinicians in achieving optimal health outcomes. The release of SnapshotGLO® complements their flagship product, SnapshotNIR®, which was first cleared by the FDA back in 2017 and has a proven track record of enhancing clinical decision-making in various healthcare settings.

As part of Kent Imaging's commitment to advancing diagnostic imaging, the Snapshot product line aims to support healthcare professionals by streamlining workflows, promoting treatment consistency, and facilitating timely interventions. By delivering devices that provide critical insights, Kent Imaging seeks to empower healthcare systems across the globe.

In a market where technology is rapidly evolving, Kent Imaging remains steadfast in its resolve. The company is ready to challenge MolecuLight's claims, ensuring that innovations such as SnapshotGLO® will continue to be accessible to clinicians everywhere. The potential impact on patient care through these advanced imaging solutions is a testament to Kent Imaging's innovative spirit and dedication to improving health outcomes.

About Kent Imaging

Located in Calgary, Alberta, Canada, Kent Imaging is renowned for developing advanced diagnostic imaging technologies. The company specializes in manufacturing medical devices that facilitate real-time decision-making in wound care and other surgical specialties. Their patented innovations are pivotal to modern healthcare, underscoring Kent Imaging's role as a leader in the medical technology landscape.

As Kent Imaging navigates through these legal challenges, its primary focus will remain on fostering innovation and supporting healthcare professionals in the pursuit of excellence in patient care. Their adaptive strategies and continuous advancements underscore a thriving organization at the forefront of the industry, with optimism for the future of medical diagnostics.

SnapshotGLO® and SnapshotNIR® are both registered trademarks of Kent Imaging Inc., symbolizing their commitment to excellence and innovation in medical imaging technology.